Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;12(8):626-31.
doi: 10.2174/138920211798120808.

New targeted therapies for thyroid cancer

Alessandro Antonelli  1 , Poupak Fallahi, Silvia M Ferrari, Ilaria Ruffilli, Francesca Santini, Michele Minuto, David Galleri, Paolo Miccoli
Affiliations

New targeted therapies for thyroid cancer

Alessandro Antonelli et al. Curr Genomics. 2011 Dec.

Abstract

The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.

Keywords: Anaplastic thyroid cancer; BRAF; RET; VEGFR.; aurora kinase inhibitors; peroxisome proliferator-activated receptor-γ; targeted molecular therapies; tyrosine kinase inhibitors.

PubMed Disclaimer

References

    1. Deshpande HA, Gettinger S, Sosa JA. Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. Core Evid. 2010;4:43–48. - PMC - PubMed
    1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 1998;338:297–306. - PubMed
    1. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J. Clin. Endocrinol. Metab. 2001;86:5627–5632. - PubMed
    1. Ward LS, Santarosa PL, Granja F, da Assumpção LV, Savoldi M, Goldman GH. Low espression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett. 2003;200:85–91. - PubMed
    1. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol. 2004;183:249–256. - PubMed